On February 28, 2023 Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, reported plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL (Press release, Agenus, FEB 28, 2023, View Source [SID1234627899]). Updated data from an expansion cohort of the Phase 1 study of botensilimab in combination with balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer will be presented at an oral plenary session on Monday, March 27th at 9:18am ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Abstract Title: Botensilimab, a Novel Innate/Adaptive Immune Activator, plus Balstilimab (Anti-PD-1) in Patients with Recurrent Platinum Refractory/Resistant Ovarian Cancer (NCT03860272)
Abstract ID: 2
Presenting Author: Bruno Bockorny, MD, Harvard University, Beth Israel Deaconess Medical Center
Details: Scientific Plenary V: Progress: Hitting Our Targets, 3/27/2023, 9:00am – 9:45am ET
The complete abstract will be available the morning of the presentation at 9:00am ET. Data presented at the conference will be available to view in the Publications section of the Agenus website (View Source) following the SGO Conference.
About Botensilimab
Botensilimab is a novel, multifunctional CTLA-4 antibody that has been designed to extend clinical benefits to "cold" tumors that do not respond to currently approved immunotherapy-only regimens. In addition to binding to the CTLA-4 receptor, its FC-enhanced structure induces memory immune response, downregulates regulatory T cells, and delivers better priming and activation of T cells, thereby amplifying immune responses.
In a Phase 1b clinical study of more than 300 patients, botensilimab has demonstrated clinical responses in nine solid tumor cancers, either alone or in combination with Agenus’ PD-1 antibody, balstilimab. Agenus is conducting global, randomized Phase 2 trials in microsatellite-stable colorectal cancer (MSS CRC), pancreatic cancer, and melanoma as part of its ACTIVATE trial program. A global Phase 3 trial in MSS CRC is planned to launch in 2023.